FOLH1 and neuroblastoma: To summarize, the highest frequencies of any dosimetry, i.e., either as part of treatment planning or post-therapy and on an Always/Majority basis (Fig. 2b, d), were for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%).